Global Liposomal Verteporfin Market Size, Share and Trends Analysis Report, By Type (Brands, Generic), By Application (Hospital and Drugs Stores), Forecast (2022-2028)

The Liposomal Verteporfin market is anticipated to grow at a significant CAGR during the forecast period (2022- 2028). As drugs, liposomes offer several advantages including biocompatibility, capacity for self-assembly, ability to carry large drugs payloads, and a wide range of physicochemical and biophysical properties that can be modified to control their biological characteristics. Verteporfin liposomes are administered intravenously. Both in vitro and in vivo studies revealed immediate and complete transfer of verteporfin from liposomes to plasma proteins, indicating no drug retention in liposomes after intravenous administration. The liposome vesicles only serve as a verteporfin solubilizer.

The market is segmented based on the type and application. Based on the type the market is sub-segmented into brands and generic. A drug that is sold by a drug company under a specific brand name or trademark and that is which is protected by a patent. A generic drug is a medication created to be the same as a marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.  Any generic medicine must perform the same in the body as the original brand name medicine. Generic medicines should meet the same high standards of quality and manufacturing as the brand-name product. Generic medicines use the same active ingredients as brand-name medicines and work the same way, so they have the same risks and benefits as brand-name medicines. By Application, the market is sub-segmented into hospital and drug stores. Medicines can also be available in hospitals or you can also buy them from drug stores that are there in the market area.

Some major players in the market include Novartis AG, Bausch & Lomb Incorporated, Pfizer Inc, Cipla Inc, and Teva Pharmaceuticals Industries Ltd.  The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, Plus Therapeutics, Inc., headquartered in the U.S., has a strong pipeline for the liposomal drug delivery system.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Novartis AG, Bausch & Lomb Incorporated, Pfizer Inc, Cipla Inc, and Teva Pharmaceuticals Industries Ltd.

 Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?

Global Liposomal Verteporfin Market Report by Segment

By Type

• Brands
• Generic

By Application

• Hospital
• Drugs Stores

Global Liposomal Verteporfin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa